US20100069426A1 - Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same - Google Patents

Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same Download PDF

Info

Publication number
US20100069426A1
US20100069426A1 US12485462 US48546209A US2010069426A1 US 20100069426 A1 US20100069426 A1 US 20100069426A1 US 12485462 US12485462 US 12485462 US 48546209 A US48546209 A US 48546209A US 2010069426 A1 US2010069426 A1 US 2010069426A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
poly
acid
lactic
therapeutic nanoparticle
ethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12485462
Other versions
US8613951B2 (en )
Inventor
Stephen E. Zale
Greg Troiano
Mir Mukkaram Ali
Jeff Hrkach
James Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
BIND Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08Lactic acid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Abstract

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.

Description

    RELATED APPLICATIONS
  • This application claims priority to U.S. Ser. No. 61/061,760, filed Jun. 16, 2008; U.S. Ser. No. 61/105,916, filed Oct. 16, 2008, U.S. Ser. No. 61/106,777, filed Oct. 20, 2008; U.S. Ser. No. 61/169,514, filed Apr. 15, 2009; U.S. Ser. No. 61/175,209, filed May 4, 2009; U.S. Ser. No. 61/061,704, filed Jun. 16, 2008; U.S. Ser. No. 61/169,519, filed Apr. 15, 2009; U.S. Ser. No. 61/175,219 filed May 4, 2009; U.S. Ser. No. 61/061,697, filed Jun. 16, 2008; U.S. Ser. No. 61/088,159, filed Aug. 12, 2008; U.S. Ser. No. 61/169,541, filed Apr. 15, 2009; U.S. Ser. No. 61/175,226, filed May 4, 2009; U.S. Ser. No. 61/173,790, filed Apr. 29, 2009; each of which is hereby incorporated by reference in their entirety.
  • BACKGROUND
  • Systems that deliver certain drugs to a patient (e.g., targeted to a particular tissue or cell type or targeted to a specific diseased tissue but not normal tissue), or that control release of drugs has long been recognized as beneficial. For example, therapeutics that include an active drug and that are capable of locating in a particular tissue or cell type e.g., a specific diseased tissue, may reduce the amount of the drug in tissues of the body that do not require treatment. This is particularly important when treating a condition such as cancer where it is desirable that a cytotoxic dose of the drug is delivered to cancer cells without killing the surrounding non-cancerous tissue. Further, such therapeutics may reduce the undesirable and sometimes life threatening side effects common in anticancer therapy. For example, nanoparticle therapeutics may, due the small size, evade recognition within the body allowing for targeted and controlled delivery while e.g., remaining stable for an effective amount of time.
  • Therapeutics that offer such therapy and/or controlled release and/or targeted therapy also must be able to deliver an effective amount of drug. It can be a challenge to prepare nanoparticle systems that have an appropriate amount of drug associated each nanoparticle, while keeping the size of the nanoparticles small enough to have advantageous delivery properties. For example, while it is desirable to load a nanoparticle with a high quantity of therapeutic agent, nanoparticle preparations that use a drug load that is too high will result in nanoparticles that are too large for practical therapeutic use. Further, it may be desirable for therapeutic nanoparticles to remain stable so as to e.g. substantially limit rapid or immediate release of the therapeutic agent.
  • Accordingly, a need exists for new nanoparticle formulations and methods of making such nanoparticles and compositions, that can deliver therapeutic levels of drugs to treat diseases such as cancer, while also reducing patient side effects.
  • SUMMARY
  • In one aspect, the invention provides therapeutic nanoparticle that includes an active agent or therapeutic agent, e.g. an mTOR inhibitor or pharmaceutically acceptable salts thereof, and one, two, or three biocompatible polymers. For example, disclosed herein is a therapeutic nanoparticle comprising about 1 to about 20 weight percent of a therapeutic agent (such as for example sirolimus, temsirolimus, or everolimus) and about 50 to about 99 weight percent of a biocompatible polymer, e.g. about 70 to about 99 weight percent of a biocompatible polymer. For example, the biocompatible polymer may be a diblock poly(lactic) acid-poly(ethylene)glycol copolymer (e.g. PLA-PEG) or a diblock (poly(lactic)-co-poly (glycolic) acid)-poly(ethylene)glycol copolymer (e.g. PLGA-PEG), or the biocompatible polymer may two or more biocompatible polymers, for example, the therapeutic nanoparticles can also include a homopolymer such as poly(lactic) acid homopolymer. For example, a disclosed therapeutic nanoparticle may include about 1 to about 20 weight percent, e.g about 2 to about 20 weight percent or about 10 to about 20 weight percent, of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer, wherein the biocompatible polymer is selected from the group consisting of a) a diblock poly(lactic) acid-poly(ethylene)glycol copolymer, b) a diblock poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer, c) a combination of a) or b) and a poly (lactic) acid homopolymer or poly(lactic)-co-(glycolic) acid; and d) a combination of a) or b) and a poly (lactic) acid homopolymer or poly(lactic)-co-(glycolic) acid.
  • The diameter of disclosed nanoparticles may be, for example, about 60 to about 120 nm, or about 70 to about 120 nm. Disclosed therapeutic nanoparticles may be stable for at least 5 days at 25° C., e.g. may remain stable over 5 days in vitro, e.g. in a sucrose solution. In another embodiment, disclosed particles may substantially immediately release less than about 2% or less than about 5%, or even less than about 10% of the therapeutic agent when placed in a phosphate buffer solution at room temperature, or at 37° C. For example, disclosed nanoparticles may substantially retain the therapeutic agent for at least 5 days at 25° C. In another embodiment, disclosed nanoparticles may release the therapeutic agent over a period of at least 1 day or more when administered to a patient.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is flow chart for an emulsion process for forming disclosed nanoparticle.
  • FIG. 2 is a flow diagram for a disclosed emulsion process.
  • FIG. 3 depicts the effect of coarse emulsion preparation on quenched particle size. Placebo organic at 30% solids was used, emulsified at 5:1 W:O using standard aqueous phase (1% sodium cholate, 2% benzyl alcohol, 4% ethyl acetate).
  • FIG. 4 depicts the effect of feed pressure on resultant particle size.
  • FIG. 5 depicts the particle size dependence on scale. Placebo organic phase consisted of 25.5% polymer stock of 50:50 16.5/5 PLA/PEG:8.2 PLA. Organic phase was emulsified 5:1 O:W with standard aqueous phase, and multiple discreet passes were performed, quenching a small portion of emulsion after each pass. The indicated scale represents the total solids of the formulation.
  • FIG. 6 depicts the effect of solids concentration on particle size.
  • FIG. 7 depicts the effect of solids concentration and poly(lactic) homopolymer on loading percentage of sirolimus (rapamycin).
  • FIG. 8 depicts in vitro release of sirolimus over time for disclosed nanoparticles
  • FIG. 9 depicts the effects of poly(lactic) homopolymer on loading percentage of temsirolimus.
  • FIG. 10 depicts the effect of solids concentration on particle size of temsirolimus containing particles.
  • FIG. 11 depicts in vitro release of temsirolimus over time for disclosed nanoparticles
  • DETAILED DESCRIPTION
  • The present invention generally relates to polymeric nanoparticles that include an active or therapeutic agent or drug, and methods of making and using such therapeutic nanoparticles. In general, a “nanoparticle” refers to any particle having a diameter of less than 1000 nm, e.g. about 10 nm to about 200 nm. Disclosed therapeutic nanoparticles may include nanoparticles having a diameter of about 60 to about 120 nm, or about 70 to about 130 nm, or about 60 to about 140 nm, or about 70 nm to about 140 nm.
  • Disclosed nanoparticles may include about 0.2 to about 35 weight percent, about 3 to about 40 weight percent, about 5 to about 30 weight percent, about 1 to about 20 weight percent, about 10 to about 30 weight percent, about 5 to about 15 percent, about 15 to 25 weight percent, or even about 4 to about 25 weight percent, e.g. about 10 weight percent of an active agent, such as antineoplastic agent, e.g. a mTOR inhibiting agent (for example sirolimus, temsirolimus or everolimus).
  • Nanoparticles disclosed herein include one, two, three or more biocompatible and/or biodegradable polymers. For example, a contemplated nanoparticle may include about 60 to about 99 weight percent of one, two, three or more biocompatible polymers such as one or more co-polymers (e.g. a diblock polymer) that include a biodegradable polymer (for example poly(lactic)acid and polyethylene glycol, and optionally about 0 to about 50 weight percent of a homopolymer, e.g. biodegradable polymer such as poly(lactic) acid.
  • Polymers
  • In some embodiments, disclosed nanoparticles include a matrix of polymers. Disclosed nanoparticles may include one or more polymers, e.g. a diblock co-polymer and/or a monopolymer. Disclosed therapeutic nanoparticles include a therapeutic agent can may associated with the surface of, encapsulated within, surrounded by, and/or dispersed throughout a polymeric matrix.
  • A wide variety of polymers and methods for forming particles therefrom are known in the art of drug delivery. In some embodiments, the disclosure is directed toward nanoparticles with at least one polymer, for example, a first polymer that may be a co-polymer, e.g. a diblock co-polymer, and optionally a polymer that may be for example a homopolymer.
  • Any polymer can be used in accordance with the present invention. Polymers can be natural or unnatural (synthetic) polymers. Polymers can be homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers can be random, block, or comprise a combination of random and block sequences. Contemplated polymers may be biocompatible and/or biodegradable.
  • The term “polymer,” as used herein, is given its ordinary meaning as used in the art, i.e., a molecular structure comprising one or more repeat units (monomers), connected by covalent bonds. The repeat units may all be identical, or in some cases, there may be more than one type of repeat unit present within the polymer. In some cases, the polymer can be biologically derived, i.e., a biopolymer. Non-limiting examples include peptides or proteins. In some cases, additional moieties may also be present in the polymer, for example biological moieties such as those described below. If more than one type of repeat unit is present within the polymer, then the polymer is said to be a “copolymer.” It is to be understood that in any embodiment employing a polymer, the polymer being employed may be a copolymer in some cases. The repeat units forming the copolymer may be arranged in any fashion. For example, the repeat units may be arranged in a random order, in an alternating order, or as a block copolymer, i.e., comprising one or more regions each comprising a first repeat unit (e.g., a first block), and one or more regions each comprising a second repeat unit (e.g., a second block), etc. Block copolymers may have two (a diblock copolymer), three (a triblock copolymer), or more numbers of distinct blocks.
  • Disclosed particles can include copolymers, which, in some embodiments, describes two or more polymers (such as those described herein) that have been associated with each other, usually by covalent bonding of the two or more polymers together. Thus, a copolymer may comprise a first polymer and a second polymer, which have been conjugated together to form a block copolymer where the first polymer can be a first block of the block copolymer and the second polymer can be a second block of the block copolymer. Of course, those of ordinary skill in the art will understand that a block copolymer may, in some cases, contain multiple blocks of polymer, and that a “block copolymer,” as used herein, is not limited to only block copolymers having only a single first block and a single second block. For instance, a block copolymer may comprise a first block comprising a first polymer, a second block comprising a second polymer, and a third block comprising a third polymer or the first polymer, etc. In some cases, block copolymers can contain any number of first blocks of a first polymer and second blocks of a second polymer (and in certain cases, third blocks, fourth blocks, etc.). In addition, it should be noted that block copolymers can also be formed, in some instances, from other block copolymers. For example, a first block copolymer may be conjugated to another polymer (which may be a homopolymer, a biopolymer, another block copolymer, etc.), to form a new block copolymer containing multiple types of blocks, and/or to other moieties (e.g., to non-polymeric moieties).
  • In some embodiments, the polymer (e.g., copolymer, e.g., block copolymer) can be amphiphilic, i.e., having a hydrophilic portion and a hydrophobic portion, or a relatively hydrophilic portion and a relatively hydrophobic portion. A hydrophilic polymer can be one generally that attracts water and a hydrophobic polymer can be one that generally repels water. A hydrophilic or a hydrophobic polymer can be identified, for example, by preparing a sample of the polymer and measuring its contact angle with water (typically, the polymer will have a contact angle of less than 60°, while a hydrophobic polymer will have a contact angle of greater than about 60°). In some cases, the hydrophilicity of two or more polymers may be measured relative to each other, i.e., a first polymer may be more hydrophilic than a second polymer. For instance, the first polymer may have a smaller contact angle than the second polymer.
  • In one set of embodiments, a polymer (e.g., copolymer, e.g., block copolymer) contemplated herein includes a biocompatible polymer, i.e., the polymer that does not typically induce an adverse response when inserted or injected into a living subject, for example, without significant inflammation and/or acute rejection of the polymer by the immune system, for instance, via a T-cell response. Accordingly, the therapeutic particles contemplated herein can be non-immunogenic. The term non-immunogenic as used herein refers to endogenous growth factor in its native state which normally elicits no, or only minimal levels of, circulating antibodies, T-cells, or reactive immune cells, and which normally does not elicit in the individual an immune response against itself.
  • Biocompatibility typically refers to the acute rejection of material by at least a portion of the immune system, i.e., a nonbiocompatible material implanted into a subject provokes an immune response in the subject that can be severe enough such that the rejection of the material by the immune system cannot be adequately controlled, and often is of a degree such that the material must be removed from the subject. One simple test to determine biocompatibility can be to expose a polymer to cells in vitro; biocompatible polymers are polymers that typically will not result in significant cell death at moderate concentrations, e.g., at concentrations of 50 micrograms/106 cells. For instance, a biocompatible polymer may cause less than about 20% cell death when exposed to cells such as fibroblasts or epithelial cells, even if phagocytosed or otherwise uptaken by such cells. Non-limiting examples of biocompatible polymers that may be useful in various embodiments of the present invention include polydioxanone (PDO), polyhydroxyalkanoate, polyhydroxybutyrate, poly(glycerol sebacate), polyglycolide, polylactide, PLGA, polycaprolactone, or copolymers or derivatives including these and/or other polymers.
  • In certain embodiments, contemplated biocompatible polymers may be biodegradable, i.e., the polymer is able to degrade, chemically and/or biologically, within a physiological environment, such as within the body. As used herein, “biodegradable” polymers are those that, when introduced into cells, are broken down by the cellular machinery (biologically degradable) and/or by a chemical process, such as hydrolysis, (chemically degradable) into components that the cells can either reuse or dispose of without significant toxic effect on the cells. In one embodiment, the biodegradable polymer and their degradation byproducts can be biocompatible.
  • For instance, a contemplated polymer may be one that hydrolyzes spontaneously upon exposure to water (e.g., within a subject), the polymer may degrade upon exposure to heat (e.g., at temperatures of about 37° C.). Degradation of a polymer may occur at varying rates, depending on the polymer or copolymer used. For example, the half-life of the polymer (the time at which 50% of the polymer can be degraded into monomers and/or other nonpolymeric moieties) may be on the order of days, weeks, months, or years, depending on the polymer. The polymers may be biologically degraded, e.g., by enzymatic activity or cellular machinery, in some cases, for example, through exposure to a lysozyme (e.g., having relatively low pH). In some cases, the polymers may be broken down into monomers and/or other nonpolymeric moieties that cells can either reuse or dispose of without significant toxic effect on the cells (for example, polylactide may be hydrolyzed to form lactic acid, polyglycolide may be hydrolyzed to form glycolic acid, etc.).
  • In some embodiments, polymers may be polyesters, including copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as “PLGA”; and homopolymers comprising glycolic acid units, referred to herein as “PGA,” and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as “PLA.” In some embodiments, exemplary polyesters include, for example, polyhydroxyacids; PEGylated polymers and copolymers of lactide and glycolide (e.g., PEGylated PLA, PEGylated PGA, PEGylated PLGA, and derivatives thereof. In some embodiments, polyesters include, for example, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), polylysine, PEGylated polylysine, poly(ethylene imine), PEGylated poly(ethylene imine), poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[α-(4-aminobutyl)-L-glycolic acid], and derivatives thereof.
  • In some embodiments, a polymer may be PLGA. PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA can be characterized by the ratio of lactic acid:glycolic acid. Lactic acid can be L-lactic acid, D-lactic acid, or D,L-lactic acid. The degradation rate of PLGA can be adjusted by altering the lactic acid-glycolic acid ratio. In some embodiments, PLGA to be used in accordance with the present invention can be characterized by a lactic acid:glycolic acid molar ratio of approximately 85:15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85.
  • In some embodiments, the ratio of lactic acid to glycolic acid monomers in the polymer of the particle (e.g., the PLGA block copolymer or PLGA-PEG block copolymer), may be selected to optimize for various parameters such as water uptake, therapeutic agent release and/or polymer degradation kinetics can be optimized.
  • In some embodiments, polymers may be one or more acrylic polymers. In certain embodiments, acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid polyacrylamide, amino alkyl methacrylate copolymer, glycidyl methacrylate copolymers, polycyanoacrylates, and combinations comprising one or more of the foregoing polymers. The acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.
  • In some embodiments, polymers can be cationic polymers. In general, cationic polymers are able to condense and/or protect negatively charged strands of nucleic acids (e.g. DNA, RNA, or derivatives thereof). Amine-containing polymers such as poly(lysine), polyethylene imine (PEI), and poly(amidoamine) dendrimers are contemplated for use, in some embodiments, in a disclosed particle.
  • In some embodiments, polymers can be degradable polyesters bearing cationic side chains. Examples of these polyesters include poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester). A polymer (e.g., copolymer, e.g., block copolymer) containing poly(ethylene glycol) repeat units can also be referred to as a “PEGylated” polymer. Such polymers can control inflammation and/or immunogenicity (i.e., the ability to provoke an immune response) and/or lower the rate of clearance from the circulatory system via the reticuloendothelial system (RES), due to the presence of the poly(ethylene glycol) groups.
  • PEGylation may also be used, in some cases, to decrease charge interaction between a polymer and a biological moiety, e.g., by creating a hydrophilic layer on the surface of the polymer, which may shield the polymer from interacting with the biological moiety. In some cases, the addition of poly(ethylene glycol) repeat units may increase plasma half-life of the polymer (e.g., copolymer, e.g., block copolymer), for instance, by decreasing the uptake of the polymer by the phagocytic system while decreasing transfection/uptake efficiency by cells. Those of ordinary skill in the art will know of methods and techniques for PEGylating a polymer, for example, by using EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) and NHS (N-hydroxysuccinimide) to react a polymer to a PEG group terminating in an amine, by ring opening polymerization techniques (ROMP), or the like.
  • Particles disclosed herein may or may not contain PEG. In addition, certain embodiments can be directed towards copolymers containing poly(ester-ether)s, e.g., polymers having repeat units joined by ester bonds (e.g., R—C(O)—O—R′ bonds) and ether bonds (e.g., R—O—R′ bonds). In some embodiments of the invention, a biodegradable polymer, such as a hydrolyzable polymer, containing carboxylic acid groups, may be conjugated with poly(ethylene glycol) repeat units to form a poly(ester-ether).
  • It is contemplated that PEG may include a terminal end group, for example, when PEG is not conjugated to a ligand. For example, PEG may terminate in a hydroxyl, a methoxy or other alkoxyl group, a methyl or other alkyl group, an aryl group, a carboxylic acid, an amine, an amide, an acetyl group, a guanidino group, or an imidazole. Other contemplated end groups include azide, alkyne, maleimide, aldehyde, hydrazide, hydroxylamine, alkoxyamine, or thiol moieties.
  • In one embodiment, the molecular weight of the polymers can be optimized for effective treatment as disclosed herein. For example, the molecular weight of a polymer may influence particle degradation rate (such as when the molecular weight of a biodegradable polymer can be adjusted), solubility, water uptake, and drug release kinetics. For example, the molecular weight of the polymer can be adjusted such that the particle biodegrades in the subject being treated within a reasonable period of time (ranging from a few hours to 1-2 weeks, 3-4 weeks, 5-6 weeks, 7-8 weeks, etc.). A disclosed particle can for example comprise a copolymer of PEG and PLGA, the PEG can have a molecular weight of 1,000-20,000, e.g., 5,000-20,000, e.g., 10,000-20,000, and the PLGA can have a molecular weight of 5,000-100,000, e.g., 20,000-70,000, e.g., 20,000-50,000.
  • For example, disclosed here is an exemplary therapeutic nanoparticle that includes about 10 to about 99 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer or poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer, or about 20 to about 80 weight percent, about 40 to about 80 weight percent, or about 30 to about 50 weight percent, or about 70 to about 90 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer or poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer. Exemplary poly(lactic) acid-poly(ethylene)glycol copolymers can include a number average molecular weight of about 15 to about 20 kDa, or about 10 to about 25 kDa of poly(lactic) acid and a number average molecular weight of about 4 to about 6, or about 2 kDa to about 10 kDa of poly(ethylene)glycol.
  • Disclosed nanoparticles may optionally include about 1 to about 50 weight percent poly(lactic) acid or poly(lactic) acid-co-poly (glycolic) acid (which does not include PEG, e.g a homopolymer of PLA), or may optionally include about 1 to about 50 weight percent, or about 10 to about 50 weight percent or about 30 to about 50 weight percent poly(lactic) acid or poly(lactic) acid-co-poly (glycolic) acid. For example, poly(lactic) or poly(lactic)-co-poly(glycolic) acid may have a number average molecule weight of about 5 to about 15 kDa, or about 5 to about 12 kDa. Exemplary homopolymeric PLA may have a number average molecular weight of about 5 to about 10 kDa. Exemplary PLGA may have a number average molecular weight of about 8 to about 12 kDa.
  • In certain embodiments, disclosed polymers of may be conjugated to a lipid, e.g. “end-capped,” for example, may include a lipid-terminated PEG. As described below, the lipid portion of the polymer can be used for self assembly with another polymer, facilitating the formation of a nanoparticle. For example, a hydrophilic polymer could be conjugated to a lipid that will self assemble with a hydrophobic polymer.
  • Exemplary lipids include fatty acids such as long chain (e.g., C8-C50), substituted or unsubstituted hydrocarbons. In some embodiments, a fatty acid group can be a C10-C20 fatty acid or salt thereof. In some embodiments, a fatty acid group can be a C15-C20 fatty acid or salt thereof. In some embodiments, a fatty acid can be unsaturated, monounsaturated, or polyunsaturated. For example, a fatty acid group can be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid. In some embodiments, a fatty acid group can be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linolenic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.
  • In a particular embodiment, the lipid is of the Formula V:
  • Figure US20100069426A1-20100318-C00001
  • and salts thereof, wherein each R is, independently, C1-30 alkyl. In one embodiment of Formula V, the lipid is 1,2 distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and salts thereof, e.g., the sodium salt.
  • In one embodiment, optional small molecule targeting moieties are bonded, e.g., covalently bonded, to the lipid component of the nanoparticle. For example, contemplated herein is also a nanoparticle comprising a therapeutic agent, a polymeric matrix comprising functionalized and non-functionalized polymers, a lipid, and a low-molecular weight targeting ligand, wherein the targeting ligand is bonded, e.g., covalently bonded, to the lipid component of the nanoparticle.
  • Targeting Moieties
  • Provided herein are nanoparticles that may include an optional targeting moiety, i.e., a moiety able to bind to or otherwise associate with a biological entity, for example, a membrane component, a cell surface receptor, prostate specific membrane antigen, or the like. A targeting moiety present on the surface of the particle may allow the particle to become localized at a particular targeting site, for instance, a tumor, a disease site, a tissue, an organ, a type of cell, etc. The drug or other payload may then, in some cases, be released from the particle and allowed to interact locally with the particular targeting site.
  • In one embodiment of the instant invention, the targeting moiety may be a low-molecular weight ligand, e.g., a low-molecular weight PSMA ligand. For example, a targeting portion may cause the particles to become localized to a tumor, a disease site, a tissue, an organ, a type of cell, etc. within the body of a subject, depending on the targeting moiety used. For example, a low-molecular weight PSMA ligand may become localized to prostate cancer cells. The subject may be a human or non-human animal. Examples of subjects include, but are not limited to, a mammal such as a dog, a cat, a horse, a donkey, a rabbit, a cow, a pig, a sheep, a goat, a rat, a mouse, a guinea pig, a hamster, a primate, a human or the like.
  • Contemplated targeting moieties include small molecules. In certain embodiments, the term “small molecule” refers to organic compounds, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have relatively low molecular weight and that are not proteins, polypeptides, or nucleic acids. Small molecules typically have multiple carbon-carbon bonds. In certain embodiments, small molecules are less than about 2000 g/mol in size. In some embodiments, small molecules are less than about 1500 g/mol or less than about 1000 g/mol. In some embodiments, small molecules are less than about 800 g/mol or less than about 500 g/mol, for example about 100 g/mol to about 600 g/mol, or about 200 g/mol to about 500 g/mol. For example, a ligand may be a the low-molecular weight PSMA ligand such as
  • Figure US20100069426A1-20100318-C00002
  • and enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
  • In some embodiments, small molecule targeting moieties that may be used to target cells associated with prostate cancer tumors include PSMA peptidase inhibitors such as 2-PMPA, GPI5232, VA-033, phenylalkylphosphonamidates and/or analogs and derivatives thereof. In some embodiments, small molecule targeting moieties that may be used to target cells associated with prostate cancer tumors include thiol and indole thiol derivatives, such as 2-MPPA and 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acid derivatives. In some embodiments, small molecule targeting moieties that may be used to target cells associated with prostate cancer tumors include hydroxamate derivatives. In some embodiments, small molecule targeting moieties that may be used to target cells associated with prostate cancer tumors include PBDA- and urea-based inhibitors, such as ZJ 43, ZJ 11, ZJ 17, ZJ 38 and/or and analogs and derivatives thereof, androgen receptor targeting agents (ARTAs), polyamines, such as putrescine, spermine, and spermidine, inhibitors of the enzyme glutamate carboxylase II (GCPII), also known as NAAG Peptidase or NAALADase.
  • In another embodiment of the instant invention, the targeting moiety can be a ligand that targets Her2, EGFR, or toll receptors. For example, contemplated the targeting moieties may include a nucleic acid, polypeptide, glycoprotein, carbohydrate, or lipid. For example, a targeting moiety can be a nucleic acid targeting moiety (e.g. an aptamer, e.g., the A10 aptamer) that binds to a cell type specific marker. In general, an aptamer is an oligonucleotide (e.g., DNA, RNA, or an analog or derivative thereof) that binds to a particular target, such as a polypeptide. In some embodiments, a targeting moiety may be a naturally occurring or synthetic ligand for a cell surface receptor, e.g., a growth factor, hormone, LDL, transferrin, etc. A targeting moiety can be an antibody, which term is intended to include antibody fragments, characteristic portions of antibodies, single chain targeting moieties can be identified, e.g., using procedures such as phage display. Targeting moieties may be a targeting peptide or targeting peptidomimetic has a length of up to about 50 residues. For example, a targeting moieties may include the amino acid sequence AKERC, CREKA, ARYLQKLN or AXYLZZLN, wherein X and Z are variable amino acids, or conservative variants or peptidomimetics thereof. In particular embodiments, the targeting moiety is a peptide that includes the amino acid sequence AKERC, CREKA, ARYLQKLN or AXYLZZLN, wherein X and Z are variable amino acids, and has a length of less than 20, 50 or 100 residues. The CREKA (Cys Arg Glu Lys Ala) peptide or a peptidomimetic thereof peptide or the octapeptide AXYLZZLN are also contemplated as targeting moieties, as well as peptides, or conservative variants or peptidomimetics thereof, that binds or forms a complex with collagen IV, or the targets tissue basement membrane (e.g., the basement membrane of a blood vessel), can be used as a targeting moiety.
  • Exemplary targeting moieties include peptides that target ICAM (intercellular adhesion molecule, e.g. ICAM-1).
  • Targeting moieties disclosed herein are typically conjugated to a disclosed polymer or copolymer (e.g. PLA-PEG), and such a polymer conjugate may form part of a disclosed nanoparticle. For example, a disclosed therapeutic nanoparticle may optionally include about 0.2 to about 10 weight percent of a PLA-PEG or PLGA-PEG, wherein the PEG is functionalized with a targeting ligand. Contemplated therapeutic nanoparticles may include, for example, about 0.2 to about 10 mole percent PLA-PEG-ligand or poly (lactic) acid co poly (glycolic) acid-PEG-ligand. For example, PLA-PEG-ligand may include a PLA with a number average molecular weight of about 10 kDa to about 20 kDa and PEG with a number average molecular weight of about 4,000 to about 8,000.
  • Nanoparticles
  • Disclosed nanoparticles may have a substantially spherical (i.e., the particles generally appear to be spherical), or non-spherical configuration. For instance, the particles, upon swelling or shrinkage, may adopt a non-spherical configuration. In some cases, the particles may include polymeric blends. For instance, a polymer blend may include a first co-polymer that includes polyethylene glycol and a second polymer.
  • Disclosed nanoparticles may have a characteristic dimension of less than about 1 micrometer, where the characteristic dimension of a particle is the diameter of a perfect sphere having the same volume as the particle. For example, the particle can have a characteristic dimension of the particle can be less than about 300 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 50 nm, less than about 30 nm, less than about 10 nm, less than about 3 nm, or less than about 1 nm in some cases. In particular embodiments, disclosed nanoparticles may have a diameter of about 70 nm-200 nm, or about 70 nm to about 180 nm, about 80 nm to about 130 nm, about 80 nm to about 120 nm.
  • In one set of embodiments, the particles can have an interior and a surface, where the surface has a composition different from the interior, i.e., there may be at least one compound present in the interior but not present on the surface (or vice versa), and/or at least one compound is present in the interior and on the surface at differing concentrations. For example, in one embodiment, a compound, such as a targeting moiety (i.e., a low-molecular weight ligand) of a polymeric conjugate of the present invention, may be present in both the interior and the surface of the particle, but at a higher concentration on the surface than in the interior of the particle, although in some cases, the concentration in the interior of the particle may be essentially nonzero, i.e., there is a detectable amount of the compound present in the interior of the particle.
  • In some cases, the interior of the particle is more hydrophobic than the surface of the particle. For instance, the interior of the particle may be relatively hydrophobic with respect to the surface of the particle, and a drug or other payload may be hydrophobic, and readily associates with the relatively hydrophobic center of the particle. The drug or other payload can thus be contained within the interior of the particle, which can shelter it from the external environment surrounding the particle (or vice versa). For instance, a drug or other payload contained within a particle administered to a subject will be protected from a subject's body, and the body may also be substantially isolated from the drug for at least a period of time.
  • For example, disclosed herein is a therapeutic polymeric nanoparticle comprising a first non-functionalized polymer; an optional second non-functionalized polymer; an optional functionalized polymer comprising a targeting moiety; and a therapeutic agent, In a particular embodiment, the first non-functionalized polymer is PLA, PLGA, or PEG, or copolymers thereof, e.g. a diblock co-polymer PLA-PEG. For example, exemplary nanoparticle may have a PEG corona with a density of about 0.065 g/cm3, or about 0.01 to about 0.10 g/cm3.
  • Disclosed nanoparticles may be stable (e.g. retain substantially all active agent) for example in a solution that may contain a saccharide, for at least about 3 days, about 4 days or at least about 5 days at room temperature, or at 25° C.
  • In some embodiments, disclosed nanoparticles may also include a fatty alcohol, which may increase the rate of drug release. For example, disclosed nanoparticles may include a C8-C30 alcohol such as cetyl alcohol, octanol, stearyl alcohol, arachidyl alcohol, docosonal, or octasonal.
  • Nanoparticles may have controlled release properties, e.g., may be capable of delivering an amount of active agent to a patient, e.g., to specific site in a patient, over an extended period of time, e.g. over 1 day, 1 week, or more. In some embodiments, disclosed nanoparticles substantially immediately releases (e.g. over about 1 minute to about 30 minutes) less than about 2%, less than about 4%, less than about 5%, or less than about 10% of an active agent (e.g. a taxane) agent, for example when places in a phosphate buffer solution at room temperature and/or at 37° C.
  • In one embodiment, the invention comprises a nanoparticle comprising 1) a polymeric matrix and 2) an amphiphilic compound or layer that surrounds or is dispersed within the polymeric matrix forming a continuous or discontinuous shell for the particle, An amphiphilic layer can reduce water penetration into the nanoparticle, thereby enhancing drug encapsulation efficiency and slowing drug release. Further, these amphipilic layer protected nanoparticles can provide therapeutic advantages by releasing the encapsulated drug and polymer at appropriate times.
  • As used herein, the term “amphiphilic” refers to a property where a molecule has both a polar portion and a non-polar portion. Often, an amphiphilic compound has a polar head attached to a long hydrophobic tail. In some embodiments, the polar portion is soluble in water, while the non-polar portion is insoluble in water. In addition, the polar portion may have either a formal positive charge, or a formal negative charge. Alternatively, the polar portion may have both a formal positive and a negative charge, and be a zwitterion or inner salt. Exemplary amphiphilic compound include, for example, one or a plurality of the following: naturally derived lipids, surfactants, or synthesized compounds with both hydrophilic and hydrophobic moieties.
  • Specific examples of amphiphilic compounds include, but are not limited to, phospholipids, such as 1,2 distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), and dilignoceroylphatidylcholine (DLPC), incorporated at a ratio of between 0.01-60 (weight lipid/w polymer), most preferably between 0.1-30 (weight lipid/w polymer). Phospholipids which may be used include, but are not limited to, phosphatidic acids, phosphatidyl cholines with both saturated and unsaturated lipids, phosphatidyl ethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, lysophosphatidyl derivatives, cardiolipin, and β-acyl-y-alkyl phospholipids. Examples of phospholipids include, but are not limited to, phosphatidylcholines such as dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipentadecanoylphosphatidylcholine dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcho-line (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC); and phosphatidylethanolamines such as dioleoylphosphatidylethanolamine or 1-hexadecyl-2-palmitoylglycerophos-phoethanolamine. Synthetic phospholipids with asymmetric acyl chains (e.g., with one acyl chain of 6 carbons and another acyl chain of 12 carbons) may also be used.
  • In a particular embodiment, an amphiphilic component may include lecithin, and/or in particular, phosphatidylcholine.
  • Preparation of Nanoparticles
  • Another aspect of the invention is directed to systems and methods of making disclosed nanoparticles. In some embodiments, using two or more different polymers (e.g., a copolymer such as a diblock copolymer and a homopolymer) properties of particles may be controlled.
  • In a particular embodiment, the methods described herein form nanoparticles that have a high amount of encapsulated therapeutic agent, for example, may include about 1 to about 40 weight percent, or about 1 to about 30 weight percent, e.g. about 10 to about 25 weight percent or about 5 to about 20 weight percent therapeutic agent.
  • In an embodiment, a nanoemulsion process is provided, such as the process represented in FIGS. 1 and 2. For example, a therapeutic agent, a first polymer (for example, PLA-PEG or PLGA-PEG) and a second polymer (e.g. (PL(G)A or PLA), with an organic solution to form a first organic phase. Such first phase may include about 5 to about 50% weight solids, e.g about 5 to about 40% solids, or about 10 to about 30% solids, e.g. about 10%, 15%, 20% solids. The first organic phase may be combined with a first aqueous solution to form a second phase. The organic solution can include, for example, acetonitrile, tetrahydrofuran, ethyl acetate, isopropyl alcohol, isopropyl acetate, dimethylformamide, methylene chloride, dichloromethane, chloroform, acetone, benzyl alcohol, Tween 80, Span 80, or the like, and combinations thereof. In an embodiment, the organic phase may include benzyl alcohol, ethyl acetate, and combinations thereof. The second phase can be between about 1 and 50 weight %, e.g., 5-40 weight %, solids. The aqueous solution can be water, optionally in combination with one or more of sodium cholate, ethyl acetate, and benzyl alcohol.
  • For example, the oil or organic phase may use solvent that is only partially miscible with the nonsolvent (water). Therefore, when mixed at a low enough ratio and/or when using water pre-saturated with the organic solvents, the oil phase remains liquid. The oil phase may bee emulsified into an aqueous solution and, as liquid droplets, sheared into nanoparticles using, for example, high energy dispersion systems, such as homogenizers or sonicators. The aqueous portion of the emulsion, otherwise known as the “water phase”, may be surfactant solution consisting of sodium cholate and pre-saturated with ethyl acetate and benzyl alcohol.
  • Emulsifying the second phase to form an emulsion phase may be performed in one or two emulsification steps. For example, a primary emulsion may be prepared, and then emulsified to form a fine emulsion. The primary emulsion can be formed, for example, using simple mixing, a high pressure homogenizer, probe sonicator, stir bar, or a rotor stator homogenizer. The primary emulsion may be formed into a fine emulsion through the use of e.g. probe sonicator or a high pressure homogenizer, e.g. by using 1, 2, 3 or more passes through a homogenizer. For example, when a high pressure homogenizer is used, the pressure used may be about 4000 to about 8000 psi, or about 4000 to about 5000 psi, e.g. 4000 or 5000 psi.
  • Either solvent evaporation or dilution may be needed to complete the extraction of the solvent and solidify the particles. For better control over the kinetics of extraction and a more scalable process, a solvent dilution via aqueous quench may be used. For example, the emulsion can be diluted into cold water to a concentration sufficient to dissolve all of the organic solvent to form a quenched phase. Quenching may be performed at least partially at a temperature of about 5° C. or less. For example, water used in the quenching may be at a temperature that is less that room temperature (e.g. about 0 to about 10° C., or about 0 to about 5° C.).
  • In some embodiments, not all of the therapeutic agent is encapsulated in the particles at this stage, and a drug solubilizer is added to the quenched phase to form a solubilized phase. The drug solubilizer may be for example, Tween 80, Tween 20, polyvinyl pyrrolidone, cyclodextran, sodium dodecyl sulfate, or sodium cholate. For example, Tween-80 may added to the quenched nanoparticle suspension to solubilize the free drug and prevent the formation of drug crystals. In some embodiments, a ratio of drug solubilizer to therapeutic agent is about 100:1 to about 10:1.
  • The solubilized phase may be filtered to recover the nanoparticles. For example, ultrafiltration membranes may be used to concentrate the nanoparticle suspension and substantially eliminate organic solvent, free drug, and other processing aids (surfactants). Exemplary filtration may be performed using a tangential flow filtration system. For example, by using a membrane with a pore size suitable to retain nanoparticles while allowing solutes, micelles, and organic solvent to pass, nanoparticles can be selectively separated. Exemplary membranes with molecular weight cut-offs of about 300-500 kDa (−5-25 nm) may be used.
  • Diafiltration may be performed using a constant volume approach, meaning the diafiltrate (cold deionized water, e.g. about 0° C. to about 5° C., or 0 to about 10° C.) may added to the feed suspension at the same rate as the filtrate is removed from the suspension. In some embodiments, filtering may include a first filtering using a first temperature of about 0 to about 5° C., or 0° C. to about 10° C., and a second temperature of about 20° C. to about 30° C., or 15° C. to about 35° C. For example, filtering may include processing about 1 to about 6 diavolumes at about 0 to about 5° C., and processing at least one diavolume (e.g. about 1 to about 3 or about 1-2 diavolumes) at about 20° C. to about 30° C.
  • After purifying and concentrating the nanoparticle suspension, the particles may be passed through one, two or more sterilizing and/or depth filters, for example, using ˜0.2 μm depth pre-filter.
  • In exemplary embodiment of preparing nanoparticles, an organic phase is formed composed of a mixture of a therapeutic agent, e.g., sirolimus, and polymer (homopolymer, and co-polymer). The organic phase may be mixed with an aqueous phase at approximately a 1:5 ratio (oil phase:aqueous phase) where the aqueous phase is composed of a surfactant and optionally dissolved solvent. A primary emulsion may then formed by the combination of the two phases under simple mixing or through the use of a rotor stator homogenizer. The primary emulsion is then formed into a fine emulsion through the use of e.g. high pressure homogenizer. Such fine emulsion may then quenched by, e.g. addition to deionized water under mixing. An exemplary quench:emulsion ratio may be about approximately 8.5:1. A solution of Tween (e.g., Tween 80) can then be added to the quench to achieve e.g. approximately 2% Tween overall, which may serves to dissolve free, unencapsulated drug. Formed nanoparticles may then be isolated through either centrifugation or ultrafiltration/diafiltration.
  • Therapeutic Agents
  • According to the present invention, any agents including, for example, therapeutic agents (e.g. anti-cancer agents), diagnostic agents (e.g. contrast agents; radionuclides; and fluorescent, luminescent, and magnetic moieties), prophylactic agents (e.g. vaccines), and/or nutraceutical agents (e.g. vitamins, minerals, etc.) may be delivered by the disclosed nanoparticles. Exemplary agents to be delivered in accordance with the present invention include, but are not limited to, small molecules (e.g. cytotoxic agents), nucleic acids (e.g., siRNA, RNAi, and microRNA agents), proteins (e.g. antibodies), peptides, lipids, carbohydrates, hormones, metals, radioactive elements and compounds, drugs, vaccines, immunological agents, etc., and/or combinations thereof. In some embodiments, the agent to be delivered is an agent useful in the treatment of cancer (e.g., an anti-neoplastic agent).
  • In a particular embodiment, the drug may be released in a controlled release manner from the particle and allowed to interact locally with the particular patient site (e.g., a tumor). The term “controlled release” is generally meant to encompass release of a substance (e.g., a drug) at a selected site or otherwise controllable in rate, interval, and/or amount. Controlled release encompasses, but is not necessarily limited to, substantially continuous delivery, patterned delivery (e.g., intermittent delivery over a period of time that is interrupted by regular or irregular time intervals), and delivery of a bolus of a selected substance (e.g., as a predetermined, discrete amount if a substance over a relatively short period of time (e.g., a few seconds or minutes)).
  • The active agent or drug may be a therapeutic agent such as an mTOR (mammalian target of rapamycin) inhibitor such as sirolimus (rapamycin), temsirolimus, or everolimus, a taxane or diterpene derivative such as paclitaxel (or its derivatives such as DHA-paclitaxel or PG-paxlitaxel) or docetaxel. In another embodiment, the active agent or drug may be a vinca alkaloid such as vinorelbine, vinblastine, vincristine, or vindesine.
  • Pharmaceutical Formulations
  • Nanoparticles disclosed herein may be combined with pharmaceutical acceptable carriers to form a pharmaceutical composition. As would be appreciated by one of skill in this art, the carriers may be chosen based on the route of administration as described below, the location of the target issue, the drug being delivered, the time course of delivery of the drug, etc.
  • The pharmaceutical compositions and particles disclosed herein can be administered to a patient by any means known in the art including oral and parenteral routes. The term “patient,” as used herein, refers to humans as well as non-humans, including, for example, mammals, birds, reptiles, amphibians, and fish. For instance, the non-humans may be mammals (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig). In certain embodiments parenteral routes are desirable since they avoid contact with the digestive enzymes that are found in the alimentary canal. According to such embodiments, inventive compositions may be administered by injection (e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
  • In a particular embodiment, disclosed nanoparticles may be administered to a subject in need thereof systemically, e.g., by IV infusion or injection.
  • Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In one embodiment, the inventive conjugate is suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) TWEEN™ 80. The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the encapsulated or unencapsulated conjugate is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.
  • Disclosed nanoparticles may be formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of nanoparticle appropriate for the patient to be treated. For any nanoparticle, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. An animal model may also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity of nanoparticles can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose is therapeutically effective in 50% of the population) and LD50 (the dose is lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices may be useful in some embodiments. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for human use.
  • In an exemplary embodiment, a pharmaceutical composition is disclosed that includes a plurality of nanoparticles each comprising a therapeutic agent; and a pharmaceutically acceptable excipient.
  • In some embodiments, a composition suitable for freezing is comtemplated, including nanoparticles disclosed herein and a solution suitable for freezing, e.g., a sugar (e.g. sucrose) solution is added to a nanoparticle suspension. The sucrose may e.g., act as a cryoprotectant to prevent the particles from aggregating upon freezing. For example, provided herein is a nanoparticle formulation comprising a plurality of disclosed nanoparticles, sucrose and water; wherein, for example, the nanoparticles/sucrose/water is are present with about 5-10%/10-15%/80-90% (w/w/w).
  • Methods of Treatment
  • In some embodiments, therapeutic particles disclosed herein may be used to treat, alleviate, ameliorate, relieve, delay onset of, inhibit progression of, reduce severity of, and/or reduce incidence of one or more symptoms or features of a disease, disorder, and/or condition. For example, disclosed therapeutic particles, that include e.g., temsirolimus may be used to treat renal cell carcinoma. In another embodiment, disclosed therapeutic particles that include e.g. everolimus or temsirolimus may be used to treat kidney cancer, glioblastoma multiforme, mantle cell lymphoma, or dermal Kaposi's sarcoma.
  • Also contemplated here are methods of treating patients that have been subject to organ transplantation, by administering disclosed nanoparticles that e.g. include sirolimus. Other methods contemplated herein include methods of treating patients having tuberous sclerosis complex, and/or autism by administering an effective amount of a disclosed nanoparticle.
  • Methods contemplated herein include, for example, a method of preventing or deterring neointimal hyperplasia in a blood vessel of a patient, for example, a patient receiving a bare metal stent in a lesion of the blood vessel, is disclosed, comprising administering a composition comprising disclosed therapeutic particles such as those that include sirolimus or everolimus. Also contemplated herein are methods of treating or preventing restenosis (e.g. in a patient receiving a stent) comprising administering disclosed nanoparticles having e.g. sirolimus or everolimus to a patient.
  • Disclosed treatment methods may comprise administering a therapeutically effective amount of the disclosed therapeutic particles to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result. In certain embodiments of the present invention a “therapeutically effective amount” is that amount effective for treating, alleviating, ameliorating, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of e.g. a cancer being treated.
  • Also provided herein are therapeutic protocols that include administering a therapeutically effective amount of an disclosed therapeutic particle to a healthy individual (i.e., a subject who does not display any symptoms of cancer and/or who has not been diagnosed with cancer). For example, healthy individuals may be “immunized” with an inventive targeted particle prior to development of cancer and/or onset of symptoms of cancer; at risk individuals (e.g., patients who have a family history of cancer; patients carrying one or more genetic mutations associated with development of cancer; patients having a genetic polymorphism associated with development of cancer; patients infected by a virus associated with development of cancer; patients with habits and/or lifestyles associated with development of cancer; etc.) can be treated substantially contemporaneously with (e.g., within 48 hours, within 24 hours, or within 12 hours of) the onset of symptoms of cancer. Of course individuals known to have cancer may receive inventive treatment at any time.
  • In other embodiments, disclosed nanoparticles may be used to inhibit the growth of cancer cells, e.g., prostate cancer cells. As used herein, the term “inhibits growth of cancer cells” or “inhibiting growth of cancer cells” refers to any slowing of the rate of cancer cell proliferation and/or migration, arrest of cancer cell proliferation and/or migration, or killing of cancer cells, such that the rate of cancer cell growth is reduced in comparison with the observed or predicted rate of growth of an untreated control cancer cell. The term “inhibits growth” can also refer to a reduction in size or disappearance of a cancer cell or tumor, as well as to a reduction in its metastatic potential. Preferably, such an inhibition at the cellular level may reduce the size, deter the growth, reduce the aggressiveness, or prevent or inhibit metastasis of a cancer in a patient. Those skilled in the art can readily determine, by any of a variety of suitable indicia, whether cancer cell growth is inhibited.
  • Inhibition of cancer cell growth may be evidenced, for example, by arrest of cancer cells in a particular phase of the cell cycle, e.g., arrest at the G2/M phase of the cell cycle. Inhibition of cancer cell growth can also be evidenced by direct or indirect measurement of cancer cell or tumor size. In human cancer patients, such measurements generally are made using well known imaging methods such as magnetic resonance imaging, computerized axial tomography and X-rays. Cancer cell growth can also be determined indirectly, such as by determining the levels of circulating carcinoembryonic antigen, prostate specific antigen or other cancer-specific antigens that are correlated with cancer cell growth. Inhibition of cancer growth is also generally correlated with prolonged survival and/or increased health and well-being of the subject.
  • EXAMPLES
  • The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.
  • Example 1 Preparation of PLA-PEG
  • The synthesis is accomplished by ring opening polymerization of d,l-lactide with α-hydroxy-ω-methoxypoly(ethylene glycol) as the macro-initiator, and performed at an elevated temperature using Tin (II) 2-Ethyl hexanoate as a catalyst, as shown below (PEG Mn≈5,000 Da; PLA Mn≈16,000 Da; PEGPLA Mn≈21,000 Da)
  • Figure US20100069426A1-20100318-C00003
  • The polymer is purified by dissolving the polymer in dichloromethane, and precipitating it in a mixture of hexane and diethyl ether. The polymer recovered from this step shall be dried in an oven.
  • Example 2 Nanoparticle Preparation—Emulsion Process
  • An organic phase is formed composed of a mixture of sirolimus and polymer (homopolymer, co-polymer, and co-polymer with ligand). The organic phase is mixed with an aqueous phase at approximately a 1:5 ratio (oil phase:aqueous phase) where the aqueous phase is composed of a surfactant and some dissolved solvent. In order to achieve high drug loading, about 30% solids in the organic phase is used.
  • The primary, coarse emulsion is formed by the combination of the two phases under simple mixing or through the use of a rotor stator homogenizer. The rotor/stator yielded a homogeneous milky solution, while the stir bar produced a visibly larger coarse emulsion. It was observed that the stir bar method resulted in significant oil phase droplets adhering to the side of the feed vessel, suggesting that while the coarse emulsion size is not a process parameter critical to quality, it should be made suitably fine in order to prevent yield loss or phase separation. Therefore the rotor stator is used as the standard method of coarse emulsion formation, although a high speed mixer may be suitable at a larger scale.
  • The primary emulsion is then formed into a fine emulsion through the use of a high pressure homogenizer. The size of the coarse emulsion does not significantly affect the particle size after successive passes (1-3) through the homogenizer. M-110-EH (FIG. 3).
  • Homogenizer feed pressure was found to have a significant impact on resultant particle size. On both the pneumatic and electric M-110EH homogenizers, it was found that reducing the feed pressure also reduced the particle size (FIG. 4). Therefore the standard operating pressure used for the M-110EH is 4000-5000 psi per interaction chamber, which is the minimum processing pressure on the unit. The M-110EH also has the option of one or two interaction chambers. It comes standard with a restrictive Y-chamber, in series with a less restrictive 200 μm Z-chamber. It was found that the particle size was actually reduced when the Y-chamber was removed and replaced with a blank chamber. Furthermore, removing the Y-chamber significantly increases the flow rate of emulsion during processing.
  • After 2-3 passes the particle size was not significantly reduced, and successive passes can even cause a particle size increase. The results are summarized in FIG. 5.
  • The effect of scale on particle size showed surprising scale dependence. The trend shows that in the 2-10 g batch size range, larger batches produce smaller particles. It has been demonstrated that this scale dependence is eliminated when considering greater than 10 g scale batches. The amount of solids used in the oil phase was about 30%. FIG. 6 depicts the effect of solids concentration on particle size.
  • Table A summarizes the emulsification process parameters.
  • TABLE A
    Parameter Value Observation
    Coarse emulsion Rotor stator Coarse emulsion size does not affect final particle size, but large
    formation homogenizer coarse emulsion can cause increased oil phase retention in feed vessel
    Homogenizer feed 4000-5000 psi per Lower pressure reduces particle size
    pressure chamber
    Interaction 2 × 200 μm Z- 200 μm Z-chamber yields the smallest particle size, and allows for
    chamber(s) chamber highest homogenizer throughput
    Number of 2-3 passes Studies have shown that the particle size is not significantly reduced
    homogenizer passes after 2 discreet passes, and size can even increase with successive
    passes
    Water phase 0.1% [Sodium cholate] can effectively alter particle size; value is optimized
    [sodium cholate] for given process and formulation
    W:O ratio 5:1 Lowest ratio without significant particle size increase is ~5:1
    [Solids] in oil phase 30% Increased process efficiency, increased drug encapsulation, workable
    viscosity
  • The fine emulsion is then quenched by addition to deionized water at a given temperature under mixing. In the quench unit operation, the emulsion is added to a cold aqueous quench under agitation. This serves to extract a significant portion of the oil phase solvents, effectively hardening the nanoparticles for downstream filtration. Chilling the quench significantly improved drug encapsulation. The quench:emulsion ratio is approximately 5:1.
  • A solution of 35% (wt %) of Tween 80 is added to the quench to achieve approximately 2% Tween 80 overall After the emulsion is quenched a solution of Tween-80 is added which acts as a drug solubilizer, allowing for effective removal of unencapsulated drug during filtration. Table B indicates each of the quench process parameters.
  • TABLE B
    Summary quench process parameters.
    Parameter Value Observation
    Initial quench <5° C. Low temperature yields higher
    temperature drug encapsulation
    [Tween-80] solution 35% Highest concentration that
    can be prepared and readily
    disperses in quench
    Tween-80:drug ratio 25:1 Minimum amount of Tween-80
    required to effectively remove
    unencapsulated drug
    Q:E ratio  5:1 Minimum Q:E ratio while
    retaining high drug
    encapsulation
    Quench ≦5° C. Temperature which prevents
    hold/processing temp (with current significant drug leaching during
    5:1 Q:E ratio, quench hold time and initial
    25:1 Tween- concentration step
    80:drug ratio)
  • The temperature must remain cold enough with a dilute enough suspension (low enough concentration of solvents) to remain below the Tg of the particles. If the Q:E ratio is not high enough, then the higher concentration of solvent plasticizes the particles and allows for drug leakage. Conversely, colder temperatures allow for high drug encapsulation at low Q:E ratios (to ˜3:1), making it possible to run the process more efficiently.
  • The nanoparticles are then isolated through a tangential flow filtration process to concentrate the nanoparticle suspension and buffer exchange the solvents, free drug, and drug solubilizer from the quench solution into water. A regenerated cellulose membrane is used with a molecular weight cutoffs (MWCO) of 300.
  • A constant volume diafiltration (DF) is performed to remove the quench solvents, free drug and Tween-80. To perform a constant-volume DF, buffer is added to the retentate vessel at the same rate the filtrate is removed. The process parameters for the TFF operations are summarized in Table C. Crossflow rate refers to the rate of the solution flow through the feed channels and across the membrane. This flow provides the force to sweep away molecules that can foul the membrane and restrict filtrate flow. The transmembrane pressure is the force that drives the permeable molecules through the membrane.
  • TABLE C
    TFF Parameters
    Optimized
    Parameter Value Effect
    Membrane Regenerated No difference in performance between RC and PES, but
    Material cellulose - solvent compatibility is superior for RC.
    Coarse Screen
    Membrane
    Molecular Weight 300 kDa No difference in NP characteristics (i.e. residual
    Cut off tween)Increase in flux rates is seen with 500 kDa
    membrane but 500 kDa is not available in RC
    Crossflow Rate 11 L/min/m2 Higher crossflow rate led to higher flux
    Transmembrane 20 psid Open channel membranes have maximum flux rates
    Pressure between 10 and 30 psid. Coarse channel membranes have
    maximum flux rates with min TMP (~20 psid).
    Concentration of 30 mg/ml Diafiltration is most efficient at [NP] ~50 mg/ml with
    Nanoparticle open channel TFF membranes based on flux rates and
    Suspension for throughput. With coarse channel membranes the flux rate
    Diafiltration is optimized at ~30 mg/ml in the starting buffer.
    Number of ≧15 (based on About 15 diavolumes are needed to effectively remove
    Diavolumes flux increase) tween-80. End point of diafiltration is determined by in-
    process control (flux increase plateau).
    Membrane Area ~1 m2/kg Membranes sized based on anticipated flux rates and
    volumes required.
  • The filtered nanoparticle slurry is then thermal cycled to an elevated temperature during workup. A small portion (typically 5-10%) of the encapsulated drug is released from the nanoparticles very quickly after its first exposure to 25° C. Because of this phenomenon, batches that are held cold during the entire workup are susceptible to free drug or drug crystals forming during delivery or any portion of unfrozen storage. By exposing the nanoparticle slurry to elevated temperature during workup, this ‘loosely encapsulated’ drug can be removed and improve the product stability at the expense of a small drop in drug loading. 5 diavolumes is used as the amount for cold processing prior to the 25° C. treatment.
  • After the filtration process the nanoparticle suspension is passed through a sterilizing grade filter (0.2 μm absolute). Pre-filters are used to protect the sterilizing grade filter in order to use a reasonable filtration area/time for the process. Values are as summarized in Table D.
  • TABLE D
    Parameter O Value Effect
    Nanoparticle    50 mg/ml Yield losses are higher at higher [NP],
    Suspension but the ability to filter at 50 mg/ml
    Concentration obviates the need to aseptically
    concentrate after filtration
    Filtration flow ~1.3 L/min/m2 Filterability decreases as flow rate
    rate increases
  • The filtration train is Ertel Alsop Micromedia XL depth filter M953P membrane (0.2 μm Nominal); Pall SUPRAcap with Seitz EKSP depth filter media (0.1-0.3 μm Nominal); Pall Life Sciences Supor EKV 0.65/0.2 micron sterilizing grade PES filter.
  • 0.2 m2 of filtration surface area per kg of nanoparticles for depth filters and 1.3 m2 of filtration surface area per kg of nanoparticles for the sterilizing grade filters can be used.
  • Example 3 Cryoprotectant
  • Freezing a suspension of nanoemulsion nanoparticles in deionized water alone results in particle aggregation. This is believed to be due to crystallization and entanglement of PEG chains on the nanoparticle surfaces. Sugar-based excipients (sucrose, trehalose, or mannitol) can act to cryoprotect these nanoparticles under freeze/thaw conditions, with a concentrations as low as 1 wt % for dilute (˜10 mg/ml) nanoparticle suspensions. One formulation includes 10 wt % sucrose, which contains excess sucrose to what is required and is the same osmolality as physiological saline.
  • Table E shows that 16/5 PLA-PEG co-polymer is less susceptible to freeze-thaw aggregation.
  • TABLE E
    Post-
    Original F/T
    Median Median Post-F/T Post-F/T
    PSD/ PS Poly- Baseline
    Description PD (nm) dispersity Index
    1:1 45/5 and PLA 143.4, 0.124 358.9 0.358 0.0/23.16%
    (baseline)
    16/5 PLA-PEG and 186.7, 0.080 189.5 0.126 9.7/91.57%
    PLA (1:1)
    2:1:1 16/5:PLA:cetyl 174.1, 0.084 232.7 0.146 0.0/61.19%
    2:1:1 45/5:PLA:cetyl 111.0, 0.182 0 0 0.0/1.55%
    16/5 PLA-PEG alone 218.8, 0.098 226.9 0.03 7.3/60.56%
    16/5 PLA-PEG and 222.2, 0.126 230.7 0.065 4.1/35.36%
    PLA (3:1)
    45/5 PLGA-PEG and 162.7, 0.099 178.6 0.091 7.7/95.41%
    PLA (3:1)
    2:1:1 45/5 PLA- 115.9, 0.154 734.6 0.392 0.0/13.27%
    PEG:PLA:cetyl
  • Example 4 In Vitro Release
  • An in vitro release method is used to determine the initial burst phase release from nanoparticles at both ambient and 37° C. conditions. In order to maintain sink conditions and prevent nanoparticles from entering the release samples, a dialysis system was designed. After obtaining an ultracentrifuge capable of pelleting 100 nm particles, the dialysis membranes were eliminated and centrifugation was used to separate released drug from encapsulated drug.
  • The dialysis system is as follows: 3 mL slurry of sirolimus nanoparticles (approx 250 μg/mL sirolimus PLGA/PLA nanoparticles, corresponding to 2.5 mg/mL solid concentration) in DI-water is placed into the inner tube of a 300 kDa MWCO dialyzer by pipetting. The nanoparticle is suspension in this media. The dialyzer is placed into a glass bottles containing 130 ml release media (2.5% hydroxyl beta cyclodextrin in PBS), which is continually stirred at 150 rpm using a shaker to prevent the formation of an unstirred water layer at the membrane/outer solution interface. At pre-determined time points, aliquot of samples (1 mL) were withdrawn from the outer solution (dialysate) and analyzed for sirolimus concentration by HPLC.
  • The centrifugal system is run using similar conditions at lower suspension volumes without dialysis bags. Samples are centrifuged at 60,000 g for 30 minutes and the supernatant is assayed for sirolimus content to measured released sirolimus.
  • Example 5 Particle Size Analysis
  • Particle size is analyzed by two techniques—dynamic light scattering (DLS) and laser diffraction. DLS is performed using a Brookhaven ZetaPals instrument at 25° C. in dilute aqueous suspension using a 660 nm laser scattered at 90° and analyzed using the Cumulants and NNLS methods (TP008). Laser diffraction is performed with a Horiba LS950 instrument in dilute aqueous suspension using both a HeNe laser at 633 nm and an LED at 405 nm, scattered at 90° and analyzed using the Mie optical model (TP009). The output from the DLS is associated with the hydrodynamic radius of the particles, which includes the PEG ‘corona’, while the laser diffraction instrument is more closely associated with the geometric size of the PLA particle ‘core’.
  • Example 6
  • Nanoparticle batches were prepared using the general procedure of Example 2, with 80% (w/w) Polymer-PEG or Polymer-PEG with homopolymer PLA at 40% (w/w) each, with a batch of % total solids of 5%, 15% and 30%. Solvents used were: 21% benzyl alcohol and 79% ethyl acetate (w/w). For each 2 gram batch size, 400 mg of drug was used and 1.6 g of 16-5 Polymer-PEG or 0.8 g of 16-5 Polymer-PEG+0.8 g of 10 kDa PLA (homopolymer) was used. The diblock polymer 16-5 PLA-PEG or PLGA-PEG (50:50 L:G) was used, and if used, the homopolymer: PLA with a Mn=6.5 kDa, Mw=10 kDa, and Mw/Mn=1.55.
  • The organic phase (drug and polymer) is prepared in 2 g batches: To 20 mL scintillation vial add drug and polymer(s). The mass of solvents needed at % solids concentration is shown below:
  • i. 5% solids: 7.98 g benzyl alcohol+30.02 g ethyl acetate
  • ii. 15% solids: 2.38 g benzyl alcohol+8.95 g ethyl acetate
  • iii. 30% solids: 0.98 g benzyl alcohol+3.69 g ethyl acetate
  • An aqueous solution is prepared with 0.5% sodium cholate, 2% benzyl alcohol, and 4% ethyl acetate in water. To a 2 L bottle add 7.5 g sodium cholate, 1402.5 g of DI water, 30 g of benzyl alcohol and 60 g of ethyl acetate, and mix on stir plate until dissolved.
  • For the formation of emulsion, a ratio of aqueous phase to oil phase of 5:1 is used. The organic phase is poured into the aqueous solution and homogenized using IKA for 10 seconds at room temperature to form course emulsion. The solution is fed through the homogenizer (110S) at 9 Kpsi (45 psi on gauge) for 2 discreet passes to form nanoemulsion.
  • The emulsion is poured into quench (D.I. water) at <5 C while stirring on stir plate. Ratio of quench to emulsion is 8:1. 35% (w/w) Tween 80 is added in water to quench at ratio of 25:1 Tween 80 to drug. The nanoparticles are concentrated through TFF and the quench is concentrated on TFF with 500 kDa Pall cassette (2 membrane) to ˜100 mL. Diafiltering is used using ˜20 diavolumes (2 liter) of cold DI water, and the volume is brought down to minimal volume then collect final slurry, ˜100 mL. The solids concentration of unfiltered final slurry is determined by the using tared 20 mL scintillation vial and adding 4 mL final slurry and dry under vacuum on lyo/oven and the weight of nanoparticles in the 4 mL of slurry dried down is determined. Concentrated sucrose (0.666 g/g) is added to final slurry sample to attain 10% sucrose.
  • Solids concentration of 0.45 um filtered final slurry was determined by filtering about 5 mL of final slurry sample before addition of sucrose through 0.45 μm syringe filter; to tared 20 mL scintillation vial add 4 mL of filtered sample and dry under vacuum on lyo/oven.
  • The remaining sample of unfiltered final slurry was frozen with sucrose. Rapamycin (sirolimus) formulations:
  • Drug Release of Drug (t = hr)
    Name Polymer Size (nm) Loading T = 0 T = 2 T = 4 T = 24
     5% Solid 16/5 PLA/PEG 123.1 3.61% ND ND ND ND
    16/5 PLA/PEG + PLA 119.7 4.49% ND ND ND ND
    15% Solid 16/5 PLA/PEG 82.1 4.40% ND ND ND ND
    16/5 PLA/PEG + PLA 120.6 11.51%  ND ND ND ND
    23% Solid 16/5 PLA/PEG 88.1 7.40% ND ND ND ND
    16/5 PLA/PEG + PLA 118.3  7.8% ND ND ND ND
    30% Solid 16/5 PLA/PEG 88.5 10.26%  8.5 17.3 22.4 64.2
    16/5 PLA/PEG + PLA 118.3 10.18%  9.3 30.4 44.7 98.2
  • The effect of solid contents and the inclusions of poly(lactic) acid homopolymer is shown in FIG. 7.
  • In-vitro release experiments are studied by dispersing nanoparticles in PBS containing 10% (w/w) of Tween 20 (T20) at 37° C. T20 was used to increase the solubility of rapamycin in PBS to levels well detectable by HPLC as well as maintaining the sink condition. 3 mL of drug-loaded nanoparticles were redispersed in 130 mL of release medium in a jar at a known concentration (approximately 250 μg/ml). These volumes were chosen to ensure that the maximum concentration of the drug in the release medium would always be less than 10% of the maximum solubility, i.e., sink conditions. The media and nanoparticle suspension is stirred at 150 rpm. At pre-determined time points, 4 ml of aliquots were centrifuged at 50,000 rpm (236,000 g) for 1 hr to separate the nanoparticles from the elution media. The elution media is injected in to a HPLC to determine drug released from the nanoparticles. The release of rapamycin showed slow and sustained release, as shown in FIG. 8.
  • Example 7
  • Nanoparticles were prepared as in Example 2 and 6, except temsirolimus was used with 30% solid content in the organic phase before emulsion:
  • Size Drug Release of Drug (t = hr)
    Name Lot # Polymer (nm) Loading T = 0 T = 2 T = 4 T = 24
    30% 45-48-1 16/5 PLA/PEG 97.5 9.9% 11.5 15.6 17.9 40.9
    Solid 45-48-2 16/5 PLA/PEG + 112.8 14.2% 9.8 22.3 29.9 88.0
    PLA
    45-100-1 16/5 PLGA/PEG + 150.3 4.6 ND ND ND ND
    PLA
    50-52-6 16/5 PLGA/PEG + ND 6.9 10.6 35.7 45.8 87.0
    PLA
  • FIG. 9 depicts the weight % of temsirolimus and FIG. 10 depicts the nanoparticle for the different polymeric nanoparticles having temsirolimus. The results of an in-vitro release experiment as in Example 6 shows the slow and sustained release of temsirolimus showed slow and sustained release, as shown in FIG. 11.
  • EQUIVALENTS
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
  • INCORPORATION BY REFERENCE
  • The entire contents of all patents, published patent applications, websites, and other references cited herein are hereby expressly incorporated herein in their entireties by reference.

Claims (35)

  1. 1. A therapeutic nanoparticle comprising:
    about 1 to about 20 weight percent of a mTOR inhibitor; and
    about 50 to about 99 weight percent biocompatible polymer, wherein the biocompatible polymer is selected from the group consisting of
    a) a diblock poly(lactic) acid-poly(ethylene)glycol copolymer,
    b) a diblock poly(lactic)-co-(glycolic) acid-poly(ethylene)glycol copolymer,
    c) a combination of a) and a poly (lactic) acid homopolymer or poly (lactic)-co-glycolic acid); and
    d) a combination of b) and a poly (lactic) acid homopolymer or poly(lactic)-co-(glycolic) acid.
  2. 2. The therapeutic nanoparticle of claim 1 wherein said mTOR inhibitor is sirolimus, temsirolimus, or everolimus or a pharmaceutically acceptable salt thereof.
  3. 3. The therapeutic nanoparticle of claim 1, wherein the diameter of the therapeutic nanoparticle is about 70 to about 140 nm.
  4. 4. The therapeutic nanoparticle of claim 1, wherein the diameter is about 80 to about 130 nm.
  5. 5. The therapeutic nanoparticle of claim 1, comprising about 9 to about 16 weight percent of an mTOR inhibitor.
  6. 6. The therapeutic nanoparticle of claim 1, wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa.
  7. 7. The therapeutic nanoparticle of claim 1, wherein said diblock poly(lactic)-co-glycolic acid-poly(ethylene)glycol copolymer comprises poly(lactic acid)-co-gycolic acid having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa.
  8. 8. The therapeutic nanoparticle of claim 1, wherein the particle substantially immediately releases less than about 2% of the mTOR inhibitor when placed in a phosphate buffer solution at room temperature.
  9. 9. The therapeutic nanoparticle of claim 1, wherein the particle substantially immediately releases less than about 7% of the mTOR inhibitor when placed in a phosphate buffer solution at room temperature.
  10. 10. The therapeutic nanoparticle of claim 1, wherein the particle substantially immediately releases less than about 10% of the mTOR inhibitor when placed in a phosphate buffer solution at 37° C.
  11. 11. The therapeutic nanoparticle of claim 1, wherein the biocompatible polymer is diblock poly(lactic) acid-poly(ethylene)glycol copolymer.
  12. 12. The therapeutic nanoparticle of claim 1, wherein the therapeutic nanoparticle comprises about 40 to about 50 weight percent diblock poly(lactic)acid-poly(ethylene)glycol copolymer and about 40 to about 49 weight percent poly (lactic) acid homopolymer.
  13. 13. The therapeutic nanoparticle of claim 1, wherein the poly(lactic)-co-poly (glycolic) acid portion of the diblock poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer is about 50 mole percent glycolic acid and about 50 mole percent poly(lactic) acid.
  14. 14. The therapeutic nanoparticle of claim 1, wherein the poly (lactic) acid homopolymer has a weight average molecular weight of about 8 to about 12 kDa.
  15. 15. The therapeutic nanoparticle of claim 1, wherein the poly (lactic) acid homopolymer has a weight average molecular weight of about 10 kDa.
  16. 16. The therapeutic nanoparticle of claim 1, wherein said diblock poly(lactic)-co-glycolic acid-poly(ethylene)glycol copolymer comprises poly(lactic acid)-co-glycolic acid having a number average molecular weight of about 16 kDa and poly(ethylene)glycol having a number average molecular weight of about 5 kDa.
  17. 17. The therapeutic nanoparticle of claim 1, wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 16 kDa and poly(ethylene)glycol having a number average molecular weight of about 5 kDa.
  18. 18. The therapeutic nanoparticle of claim 1, wherein said therapeutic nanoparticle comprises about 10 weight percent to about 20 weight percent sirolimus.
  19. 19. The therapeutic nanoparticle of claim 1, wherein said therapeutic nanoparticle comprises about 10 weight percent to about 20 weight percent temsirolimus.
  20. 20. The therapeutic nanoparticle of claim 1, further comprising about 0.2 to about 10 weight percent of a diblock poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer covalently bound to a targeting ligand.
  21. 21. A therapeutic nanoparticle comprising:
    about 2 to about 20 weight percent of a therapeutic agent selected from the group consisting of sirolimus, temsirolimus, or everolimus;
    a diblock polymer chosen from: poly(lactic) acid-poly(ethylene)glycol copolymer or a poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer; and
    optionally, a poly(lactic) acid homopolymer.
  22. 22. The therapeutic nanoparticle of claim 21, comprising about 10 to about 20 weight percent of the therapeutic agent.
  23. 23. The therapeutic nanoparticle of claim 21, wherein the poly(lactic) acid homopolymer, if present, has a weight average molecular weight of about 10 kDa.
  24. 24. The therapeutic nanoparticle of claim 21, wherein the therapeutic nanoparticle comprises about 40 to about 45 weight percent diblock polymer and about 40 to about 45 weight percent homopolymer.
  25. 25. The therapeutic nanoparticle of claim 21, wherein the particle substantially immediately releases less than about 4% of the therapeutic agent when placed in a phosphate buffer solution at room temperature.
  26. 26. The therapeutic nanoparticle of claim 21, wherein the particle substantially immediately releases less than about 2% of the therapeutic agent when placed in a phosphate buffer solution at room temperature.
  27. 27. The therapeutic nanoparticle of claim 1, further comprising cetyl alcohol.
  28. 28.-30. (canceled)
  29. 31. A method of treating dermal Kaposi's sarcoma, lymphomas, glioblastoma multiforme, mantle cell lymphoma, renal cell carcinoma, comprising administering to a patient in need thereof an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  30. 32. A method of ameliorating organ rejection after transplant in a patient in need thereof, comprising administering to the patient an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  31. 33. A method of treating, preventing or deterring restenosis in a patient in need thereof, comprising administering to the patient an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  32. 34. A method of treating or deterring neointimal hyperplasia in a patient in need thereof, comprising administering to the patient an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  33. 35. A method of treating autosomal dominant polycystic kidney disease, comprising administering to the patient an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  34. 36. A method of treating tuberous sclerosis complex, comprising administering to the patient an effective amount of a composition comprising the therapeutic nanoparticle of claim 1.
  35. 37-40. (canceled)
US12485462 2008-06-16 2009-06-16 Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same Active 2031-02-18 US8613951B2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US6176008 true 2008-06-16 2008-06-16
US6170408 true 2008-06-16 2008-06-16
US6169708 true 2008-06-16 2008-06-16
US8815908 true 2008-08-12 2008-08-12
US10591608 true 2008-10-16 2008-10-16
US10677708 true 2008-10-20 2008-10-20
US16951909 true 2009-04-15 2009-04-15
US16954109 true 2009-04-15 2009-04-15
US16951409 true 2009-04-15 2009-04-15
US17379009 true 2009-04-29 2009-04-29
US17522609 true 2009-05-04 2009-05-04
US17520909 true 2009-05-04 2009-05-04
US17521909 true 2009-05-04 2009-05-04
US12485462 US8613951B2 (en) 2008-06-16 2009-06-16 Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12485462 US8613951B2 (en) 2008-06-16 2009-06-16 Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US13910328 US8623417B1 (en) 2008-06-16 2013-06-05 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US14091343 US9579284B2 (en) 2008-06-16 2013-11-27 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13910328 Continuation US8623417B1 (en) 2008-06-16 2013-06-05 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

Publications (2)

Publication Number Publication Date
US20100069426A1 true true US20100069426A1 (en) 2010-03-18
US8613951B2 US8613951B2 (en) 2013-12-24

Family

ID=41507663

Family Applications (3)

Application Number Title Priority Date Filing Date
US12485462 Active 2031-02-18 US8613951B2 (en) 2008-06-16 2009-06-16 Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US13910328 Active US8623417B1 (en) 2008-06-16 2013-06-05 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US14091343 Active 2029-08-31 US9579284B2 (en) 2008-06-16 2013-11-27 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13910328 Active US8623417B1 (en) 2008-06-16 2013-06-05 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US14091343 Active 2029-08-31 US9579284B2 (en) 2008-06-16 2013-11-27 Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same

Country Status (2)

Country Link
US (3) US8613951B2 (en)
WO (1) WO2010005726A3 (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080268063A1 (en) * 2004-11-04 2008-10-30 Sangyong Jon Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals
US20090061010A1 (en) * 2007-03-30 2009-03-05 Massachusetts Institute Of Technology Cancer cell targeting using nanoparticles
US20100022680A1 (en) * 2006-06-23 2010-01-28 Massachusetts Institute Of Technology Microfluidic Synthesis of Organic Nanoparticles
US20100068286A1 (en) * 2008-06-16 2010-03-18 Greg Troiano Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US20100104655A1 (en) * 2008-06-16 2010-04-29 Zale Stephen E Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100203142A1 (en) * 2007-04-04 2010-08-12 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US20100233251A1 (en) * 2007-10-12 2010-09-16 Massachusetts Institute of Technology Massachusetts Vaccine Nanotechnology
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20110020388A1 (en) * 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US20110217377A1 (en) * 2008-12-15 2011-09-08 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US20110223201A1 (en) * 2009-04-21 2011-09-15 Selecta Biosciences, Inc. Immunonanotherapeutics Providing a Th1-Biased Response
US8211473B2 (en) 2009-12-11 2012-07-03 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8518963B2 (en) 2009-12-15 2013-08-27 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2013151736A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics In vivo production of proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2014152540A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051349A1 (en) * 2013-10-04 2015-04-09 Sorrento Therapeutics, Inc. Treating metastatic cancer with micellular paclitaxel
WO2015075557A2 (en) 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US20160022650A1 (en) * 2011-04-29 2016-01-28 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9314532B2 (en) 2012-08-10 2016-04-19 University Of North Texas Health Science Center Drug delivery vehicle
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
US10106490B2 (en) 2014-06-25 2018-10-23 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012019168A3 (en) 2010-08-06 2012-07-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012103182A1 (en) 2011-01-28 2012-08-02 Cerulean Pharma Inc. Method for fabricating nanoparticles
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CA2885193A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2016065306A1 (en) * 2014-10-23 2016-04-28 The Brigham And Women's Hospital, Inc. Amphiphile-polymer particles
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Citations (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5578325A (en) * 1993-07-23 1996-11-26 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6139870A (en) * 1995-12-19 2000-10-31 Aventis Pharma Sa Stabilized nanoparticles which are filterable under sterile conditions
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6265609B1 (en) * 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6346274B1 (en) * 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
US20020045582A1 (en) * 1997-12-31 2002-04-18 Alexey L. Margolin Stabilized protein crystals formulations containing them and methods of making them
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US20020119916A1 (en) * 2000-12-22 2002-08-29 Hassan Emadeldin M. Elemental nanoparticles of substantially water insoluble materials
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US20030068377A1 (en) * 2001-10-03 2003-04-10 Macromed, Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20030143184A1 (en) * 2000-05-17 2003-07-31 Min-Hyo Seo Stable polymeric micelle-type drug composition and method for the preparation thereof
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20040054190A1 (en) * 2002-01-10 2004-03-18 Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
US20040071768A1 (en) * 1999-04-01 2004-04-15 Inex Pharmaceuticals Corporation Compositions and methods for treating cancer
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US20040086544A1 (en) * 1999-09-30 2004-05-06 Chienna B.V. Polymers with bioactive agents
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20040220081A1 (en) * 2002-10-30 2004-11-04 Spherics, Inc. Nanoparticulate bioactive agents
US20040219224A1 (en) * 2001-06-21 2004-11-04 Kirill Yakovlevsky Spherical protein particles and methods for making and using them
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20040247680A1 (en) * 2003-06-06 2004-12-09 Farokhzad Omid C. Targeted delivery of controlled release polymer systems
US6841547B2 (en) * 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US20050063976A1 (en) * 1996-05-15 2005-03-24 Altarex --Medical-- Corp. Combination therapy for treating disease
US6875886B2 (en) * 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US20050136258A1 (en) * 2003-12-22 2005-06-23 Shuming Nie Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US6916788B2 (en) * 1999-12-22 2005-07-12 Samyang Corporation Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US20060002971A1 (en) * 2004-07-01 2006-01-05 Yale University Methods of treatment with drug loaded polymeric materials
US20060057219A1 (en) * 2002-05-24 2006-03-16 Nanocarrier Co., Ltd. Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection
US20060110460A1 (en) * 2001-10-10 2006-05-25 Eulalia Ferret Prolonged release biodegradable microspheres and method for preparing same
US20060165987A1 (en) * 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
US20070031402A1 (en) * 2005-08-03 2007-02-08 Immunogen Inc. Immunoconjugate formulations
US20070041901A1 (en) * 2002-06-18 2007-02-22 Diener John L Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US20070043066A1 (en) * 2005-07-11 2007-02-22 Wyeth Glutamate aggrecanase inhibitors
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20070154554A1 (en) * 2005-12-29 2007-07-05 Robert Burgermeister Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20080057102A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
US20080081074A1 (en) * 2006-05-15 2008-04-03 Massachusetts Institute Of Technology Polymers for functional particles
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20080193381A1 (en) * 2006-11-08 2008-08-14 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20080267876A1 (en) * 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
US20090053293A1 (en) * 2005-09-09 2009-02-26 Beijing Diacrid Medical Technology Co., Ltd. Nano Anticancer Micelles of Vinca Alkaloids Entrapped in Polyethylene Glycolylated Phospholipids
US20090053315A1 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-Kinetic Mixing for Pharmaceutical Applications
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20090061010A1 (en) * 2007-03-30 2009-03-05 Massachusetts Institute Of Technology Cancer cell targeting using nanoparticles
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US20090074753A1 (en) * 2004-10-14 2009-03-19 Lynch Samuel E Platelet-derived growth factor compositions and methods of use thereof
US20090155349A1 (en) * 2006-02-23 2009-06-18 Jonathan Daniel Heller Methods of treating influenza viral infections
US20090170753A1 (en) * 2006-07-26 2009-07-02 Christian Welz Capsofungin formulations
US20090317479A1 (en) * 2005-12-26 2009-12-24 Tsutomu Ishihara Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US20100008998A1 (en) * 2006-09-26 2010-01-14 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
US20100040537A1 (en) * 2008-07-08 2010-02-18 Abbott Laboratories Prostaglandin E2 Binding Proteins and Uses Thereof
US20100068285A1 (en) * 2008-06-16 2010-03-18 Zale Stephen E Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US20100087337A1 (en) * 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20100104655A1 (en) * 2008-06-16 2010-04-29 Zale Stephen E Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same
US20100104645A1 (en) * 2008-06-16 2010-04-29 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
US20100166866A1 (en) * 2003-03-26 2010-07-01 Egalet A/S Matrix compositions for controlled delivery of drug substances
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US20100226986A1 (en) * 2008-12-12 2010-09-09 Amy Grayson Therapeutic Particles Suitable for Parenteral Administration and Methods of Making and Using Same
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20100303900A1 (en) * 2000-05-25 2010-12-02 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US20100316725A1 (en) * 2009-05-27 2010-12-16 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20110159079A1 (en) * 2002-10-29 2011-06-30 Zhili Li High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof
US8003128B2 (en) * 2006-03-24 2011-08-23 Lts Lohmann Therapie-Systeme Ag Polylactide nanoparticles
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20110275704A1 (en) * 2009-12-11 2011-11-10 Greg Troiano Stable Formulations for Lyophilizing Therapeutic Particles
US20110294717A1 (en) * 2009-12-15 2011-12-01 Ali Mir M Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
US20130108668A1 (en) * 2009-12-15 2013-05-02 Maria Figueiredo Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same
US20130115293A1 (en) * 2009-12-15 2013-05-09 Abhimanyu Sabnis Therapeutic Polymeric Nanoparticles Comprising Corticosteroids and Methods of Making and Using Same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000846A1 (en) 1987-07-29 1989-02-09 The Liposome Company, Inc. Method for size separation of particles
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
JP2942508B2 (en) 1997-01-14 1999-08-30 順也 藤森 Temperature-sensitive sustained-release base, and temperature-sensitive sustained-release system
WO2000019996A1 (en) 1998-10-01 2000-04-13 Kwangju Institute Of Science And Technology Controlled drug release system of retinoic acid
DE19856432A1 (en) 1998-12-08 2000-06-15 Basf Ag Nanoparticulate core-shell systems and their use in pharmaceutical and cosmetic preparations
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
KR100418916B1 (en) 2000-11-28 2004-02-14 한국과학기술원 Process for Preparing Sustained Release Form of Micelle Employing Conjugate of Anticancer Drug and Biodegradable Polymer
KR100446101B1 (en) 2000-12-07 2004-08-30 주식회사 삼양사 Sustained delivery composition for poorly water soluble drugs
JP2004516262A (en) 2000-12-21 2004-06-03 ネクター セラピューティクス Induced phase transition method for the preparation of microparticles containing an hydrophilic active
WO2002080846A3 (en) 2001-04-03 2003-12-04 Kosan Biosciences Inc Epothilone derivatives and methods for making and using the same
US7498045B2 (en) 2001-08-31 2009-03-03 Thomas M. S. Chang Biodegradable polymeric nanocapsules and uses thereof
CN1592607A (en) 2001-10-15 2005-03-09 克里蒂泰克公司 Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US20040126400A1 (en) * 2002-05-03 2004-07-01 Iversen Patrick L. Delivery of therapeutic compounds via microparticles or microbubbles
US7521187B2 (en) 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
EP1594482A1 (en) 2003-03-26 2005-11-16 LTT Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
KR100849911B1 (en) 2003-04-03 2008-08-04 엠. 길롬므 벤테스 Tumor-targeting drug-loaded particles
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
JP2007504259A (en) 2003-09-02 2007-03-01 ノバルティス アクチエンゲゼルシャフト Cancer treatment with the epothilone
JP2006131577A (en) 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd Method for preparing nanoparticle having different particle diameters and containing sealed medicine and nanoparticle obtained by the method
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
JP2006321763A (en) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk Biocompatibilie nanoparticle and method for production of the same
WO2007024323A3 (en) 2005-06-17 2010-12-16 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
JP2010511595A (en) 2006-07-31 2010-04-15 ニューロシステック コーポレイション Free base Gashikurijin'nano particles
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN1957911A (en) 2006-12-01 2007-05-09 济南康泉医药科技有限公司 Controlled release formulation for anti entity tumour
CN101396340A (en) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 Anti-cancer sustained-released injection containing epothilone derivate
CN1969816A (en) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 Anticancer sustained release agent containing epothilone
CN1961864A (en) 2006-12-12 2007-05-16 济南帅华医药科技有限公司 Anticancer composition
CN101433520A (en) 2006-12-12 2009-05-20 济南帅华医药科技有限公司 Anticancer sustained-release agent containing epothilone
CN101396342A (en) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 Anti-cancer sustained-released injection containing epothilone derivate
CN1969818A (en) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 Anticancer sustained release injection containing epothilone derivatives
WO2008091465A3 (en) 2006-12-21 2008-12-04 Ayman Khdair Peg and targeting ligands on nanoparticle surface
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
ES2690175T3 (en) 2007-03-07 2018-11-19 Abraxis Bioscience Llc Nanoparticle comprising rapamycin and albumin as an antineoplastic agent
CN101053553B (en) 2007-03-16 2011-04-20 吉林大学 Biodegradable fluorourcacil polyester medicine-carried nanospheres and its preparation method
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
EP2156848A4 (en) 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd Low-molecule drug-containing nanoparticle having sustained release negatively charged group
US20090306120A1 (en) 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
DE102007059752A1 (en) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
WO2009084801A1 (en) 2007-12-31 2009-07-09 Samyang Corporation Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
WO2010005726A3 (en) 2008-06-16 2010-04-22 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
WO2010114768A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CN102740895B (en) 2009-12-23 2016-02-24 伊利诺伊大学董事会 Nano nano-conjugate and conjugate formulation
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012040513A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc Therapeutic nanoparticles with high molecular weight copolymers
WO2012166923A3 (en) 2011-05-31 2013-01-24 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
WO2013044219A1 (en) 2011-09-22 2013-03-28 Bind Biosciences Methods of treating cancers with therapeutic nanoparticles
US20150051181A1 (en) 2012-02-29 2015-02-19 Merck Patent Gmbh Process for producing nanoparticles laden with active ingredient
CA2885193A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
US20140178475A1 (en) 2012-09-17 2014-06-26 Bind Therapeutics, Inc. Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same

Patent Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5578325A (en) * 1993-07-23 1996-11-26 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6346274B1 (en) * 1995-03-10 2002-02-12 Roche Diagnostics Gmbh Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6139870A (en) * 1995-12-19 2000-10-31 Aventis Pharma Sa Stabilized nanoparticles which are filterable under sterile conditions
US20050063976A1 (en) * 1996-05-15 2005-03-24 Altarex --Medical-- Corp. Combination therapy for treating disease
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) * 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US20020045582A1 (en) * 1997-12-31 2002-04-18 Alexey L. Margolin Stabilized protein crystals formulations containing them and methods of making them
US6265609B1 (en) * 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US20040071768A1 (en) * 1999-04-01 2004-04-15 Inex Pharmaceuticals Corporation Compositions and methods for treating cancer
US20040086544A1 (en) * 1999-09-30 2004-05-06 Chienna B.V. Polymers with bioactive agents
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US6916788B2 (en) * 1999-12-22 2005-07-12 Samyang Corporation Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US20030143184A1 (en) * 2000-05-17 2003-07-31 Min-Hyo Seo Stable polymeric micelle-type drug composition and method for the preparation thereof
US20100303900A1 (en) * 2000-05-25 2010-12-02 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US20020119916A1 (en) * 2000-12-22 2002-08-29 Hassan Emadeldin M. Elemental nanoparticles of substantially water insoluble materials
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US6875886B2 (en) * 2001-02-07 2005-04-05 Beth Israel Deaconess Medical Center, Inc. Modified PSMA ligands and uses related thereto
US20040219224A1 (en) * 2001-06-21 2004-11-04 Kirill Yakovlevsky Spherical protein particles and methods for making and using them
US20030068377A1 (en) * 2001-10-03 2003-04-10 Macromed, Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US20060110460A1 (en) * 2001-10-10 2006-05-25 Eulalia Ferret Prolonged release biodegradable microspheres and method for preparing same
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20040054190A1 (en) * 2002-01-10 2004-03-18 Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
US20060165987A1 (en) * 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
US6890950B2 (en) * 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
US20060057219A1 (en) * 2002-05-24 2006-03-16 Nanocarrier Co., Ltd. Method for preparing a polymer micelle pharmaceutical preparation containing drug for injection
US20070041901A1 (en) * 2002-06-18 2007-02-22 Diener John L Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US20110159079A1 (en) * 2002-10-29 2011-06-30 Zhili Li High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof
US20040220081A1 (en) * 2002-10-30 2004-11-04 Spherics, Inc. Nanoparticulate bioactive agents
US6841547B2 (en) * 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20100166866A1 (en) * 2003-03-26 2010-07-01 Egalet A/S Matrix compositions for controlled delivery of drug substances
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050037075A1 (en) * 2003-06-06 2005-02-17 Farokhzad Omid C. Targeted delivery of controlled release polymer systems
US20040247680A1 (en) * 2003-06-06 2004-12-09 Farokhzad Omid C. Targeted delivery of controlled release polymer systems
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US20050136258A1 (en) * 2003-12-22 2005-06-23 Shuming Nie Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060002971A1 (en) * 2004-07-01 2006-01-05 Yale University Methods of treatment with drug loaded polymeric materials
US20060002852A1 (en) * 2004-07-01 2006-01-05 Yale University Targeted and high density drug loaded polymeric materials
US20090074753A1 (en) * 2004-10-14 2009-03-19 Lynch Samuel E Platelet-derived growth factor compositions and methods of use thereof
US20070043066A1 (en) * 2005-07-11 2007-02-22 Wyeth Glutamate aggrecanase inhibitors
US20070031402A1 (en) * 2005-08-03 2007-02-08 Immunogen Inc. Immunoconjugate formulations
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20090053293A1 (en) * 2005-09-09 2009-02-26 Beijing Diacrid Medical Technology Co., Ltd. Nano Anticancer Micelles of Vinca Alkaloids Entrapped in Polyethylene Glycolylated Phospholipids
US20080267876A1 (en) * 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
US20090317479A1 (en) * 2005-12-26 2009-12-24 Tsutomu Ishihara Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US20070154554A1 (en) * 2005-12-29 2007-07-05 Robert Burgermeister Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20090155349A1 (en) * 2006-02-23 2009-06-18 Jonathan Daniel Heller Methods of treating influenza viral infections
US8003128B2 (en) * 2006-03-24 2011-08-23 Lts Lohmann Therapie-Systeme Ag Polylactide nanoparticles
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20080081074A1 (en) * 2006-05-15 2008-04-03 Massachusetts Institute Of Technology Polymers for functional particles
US20090170753A1 (en) * 2006-07-26 2009-07-02 Christian Welz Capsofungin formulations
US20080057102A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
US20100008998A1 (en) * 2006-09-26 2010-01-14 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
US20080193381A1 (en) * 2006-11-08 2008-08-14 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US20090061010A1 (en) * 2007-03-30 2009-03-05 Massachusetts Institute Of Technology Cancer cell targeting using nanoparticles
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US20090053315A1 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-Kinetic Mixing for Pharmaceutical Applications
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20120004293A1 (en) * 2007-09-28 2012-01-05 Zale Stephen E Cancer Cell Targeting Using Nanoparticles
US20110224288A1 (en) * 2007-09-28 2011-09-15 Zale Stephen E Cancer Cell Targeting Using Nanoparticles
US20100104655A1 (en) * 2008-06-16 2010-04-29 Zale Stephen E Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same
US20100068285A1 (en) * 2008-06-16 2010-03-18 Zale Stephen E Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US20100068286A1 (en) * 2008-06-16 2010-03-18 Greg Troiano Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US20100104645A1 (en) * 2008-06-16 2010-04-29 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
US20110274759A1 (en) * 2008-06-16 2011-11-10 Greg Troiano Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US20100040537A1 (en) * 2008-07-08 2010-02-18 Abbott Laboratories Prostaglandin E2 Binding Proteins and Uses Thereof
US20100087337A1 (en) * 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20100226986A1 (en) * 2008-12-12 2010-09-09 Amy Grayson Therapeutic Particles Suitable for Parenteral Administration and Methods of Making and Using Same
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US20110217377A1 (en) * 2008-12-15 2011-09-08 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US20130034608A1 (en) * 2008-12-15 2013-02-07 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US20100316725A1 (en) * 2009-05-27 2010-12-16 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20110275704A1 (en) * 2009-12-11 2011-11-10 Greg Troiano Stable Formulations for Lyophilizing Therapeutic Particles
US8211473B2 (en) * 2009-12-11 2012-07-03 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US20110294717A1 (en) * 2009-12-15 2011-12-01 Ali Mir M Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
US20130108668A1 (en) * 2009-12-15 2013-05-02 Maria Figueiredo Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same
US20130115293A1 (en) * 2009-12-15 2013-05-09 Abhimanyu Sabnis Therapeutic Polymeric Nanoparticles Comprising Corticosteroids and Methods of Making and Using Same

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20080268063A1 (en) * 2004-11-04 2008-10-30 Sangyong Jon Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US20100266491A1 (en) * 2006-03-31 2010-10-21 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8802153B2 (en) 2006-03-31 2014-08-12 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8709483B2 (en) 2006-03-31 2014-04-29 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100022680A1 (en) * 2006-06-23 2010-01-28 Massachusetts Institute Of Technology Microfluidic Synthesis of Organic Nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20090061010A1 (en) * 2007-03-30 2009-03-05 Massachusetts Institute Of Technology Cancer cell targeting using nanoparticles
US8246968B2 (en) 2007-03-30 2012-08-21 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US20100203142A1 (en) * 2007-04-04 2010-08-12 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US10071056B2 (en) 2007-09-28 2018-09-11 Pfizer Inc. Cancer cell targeting using nanoparticles
US9295727B2 (en) 2007-09-28 2016-03-29 Bind Therapeutics, Inc. Cancer cell targeting using nanoparticles
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US20100233251A1 (en) * 2007-10-12 2010-09-16 Massachusetts Institute of Technology Massachusetts Vaccine Nanotechnology
US9526702B2 (en) 2007-10-12 2016-12-27 Massachusetts Institute Of Technology Vaccine nanotechnology
US9579386B2 (en) 2008-06-16 2017-02-28 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9393310B2 (en) 2008-06-16 2016-07-19 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8420123B2 (en) 2008-06-16 2013-04-16 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9351933B2 (en) 2008-06-16 2016-05-31 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8603534B2 (en) 2008-06-16 2013-12-10 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8609142B2 (en) 2008-06-16 2013-12-17 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US20100104655A1 (en) * 2008-06-16 2010-04-29 Zale Stephen E Therapeutic Polymeric Nanoparticles Comprising Vinca Alkaloids and Methods of Making and Using Same
US8613954B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8617608B2 (en) 2008-06-16 2013-12-31 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8623417B1 (en) 2008-06-16 2014-01-07 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same
US8293276B2 (en) 2008-06-16 2012-10-23 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US20100068286A1 (en) * 2008-06-16 2010-03-18 Greg Troiano Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
US8652528B2 (en) 2008-06-16 2014-02-18 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8663700B2 (en) 2008-06-16 2014-03-04 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8206747B2 (en) 2008-06-16 2012-06-26 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8318208B1 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
US9308179B2 (en) 2008-12-15 2016-04-12 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US20110217377A1 (en) * 2008-12-15 2011-09-08 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US9198874B2 (en) 2008-12-15 2015-12-01 Bind Therapeutics, Inc. Long circulating nanoparticles for sustained release of therapeutic agents
US20110223201A1 (en) * 2009-04-21 2011-09-15 Selecta Biosciences, Inc. Immunonanotherapeutics Providing a Th1-Biased Response
US9884112B2 (en) 2009-05-27 2018-02-06 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US9006254B2 (en) 2009-05-27 2015-04-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US20110020388A1 (en) * 2009-05-27 2011-01-27 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
US8603535B2 (en) 2009-12-11 2013-12-10 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8956657B2 (en) 2009-12-11 2015-02-17 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8916203B2 (en) 2009-12-11 2014-12-23 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8637083B2 (en) 2009-12-11 2014-01-28 Bind Therapeutics, Inc. Stable formulations for lyophilizing therapeutic particles
US8211473B2 (en) 2009-12-11 2012-07-03 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
US8912212B2 (en) 2009-12-15 2014-12-16 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US8518963B2 (en) 2009-12-15 2013-08-27 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9835572B2 (en) 2009-12-15 2017-12-05 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9764031B2 (en) 2010-05-26 2017-09-19 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US20160022650A1 (en) * 2011-04-29 2016-01-28 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013151736A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics In vivo production of proteins
US9314532B2 (en) 2012-08-10 2016-04-19 University Of North Texas Health Science Center Drug delivery vehicle
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152540A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015051349A1 (en) * 2013-10-04 2015-04-09 Sorrento Therapeutics, Inc. Treating metastatic cancer with micellular paclitaxel
WO2015075557A2 (en) 2013-11-22 2015-05-28 Mina Alpha Limited C/ebp alpha compositions and methods of use
US10106490B2 (en) 2014-06-25 2018-10-23 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
WO2017112943A1 (en) 2015-12-23 2017-06-29 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies

Also Published As

Publication number Publication date Type
WO2010005726A3 (en) 2010-04-22 application
US20130344158A1 (en) 2013-12-26 application
US20140186453A1 (en) 2014-07-03 application
US8623417B1 (en) 2014-01-07 grant
US9579284B2 (en) 2017-02-28 grant
WO2010005726A2 (en) 2010-01-14 application
US8613951B2 (en) 2013-12-24 grant

Similar Documents

Publication Publication Date Title
Olivier Drug transport to brain with targeted nanoparticles
Kalaria et al. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats
Bala et al. PLGA nanoparticles in drug delivery: the state of the art
US8563041B2 (en) Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100015050A1 (en) Peg and targeting ligands on nanoparticle surface
US20030235619A1 (en) Polymer-lipid delivery vehicles
US20120121718A1 (en) Compositions and methods relating to reduced mucoadhesion
Devalapally et al. Poly (ethylene oxide)-modified poly (beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model
US20060177495A1 (en) Polymer-lipid delivery vehicles
EP1985309A1 (en) Nanoparticle containing water-soluble non-peptidic low molecular weight substance
Xiao et al. Recent advances in PEG–PLA block copolymer nanoparticles
Xin et al. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly (ɛ-caprolactone) nanoparticles: in vitro and in vivo evaluation
Shah et al. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic® P85, an in vitro cell line and in vivo biodistribution studies on rat model
Devalapally et al. Paclitaxel and ceramide co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
WO2013155493A1 (en) Methods of treating inflammatory and autoimmune diseases and disorders
Liu et al. Poly (ω-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery
US8003128B2 (en) Polylactide nanoparticles
Sawyer et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors
US20110294717A1 (en) Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
US20130101672A1 (en) Nanoconjugates and nanoconjugate formulations
US8293276B2 (en) Drug loaded polymeric nanoparticles and methods of making and using same
US20100216804A1 (en) Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2014043618A1 (en) Process for preparing therapeutic nanoparticles
JP2002507976A (en) New formulations of pharmacological drugs, their preparation and their use
US20060078624A1 (en) Microparticles and nanoparticles containing a lipopolymer

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIND BIOSCIENCES, INC.,MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZALE, STEPHEN E.;TROIANO, GREG;ALI, MIR MUKKARAM;AND OTHERS;SIGNING DATES FROM 20091120 TO 20091123;REEL/FRAME:023593/0493

Owner name: BIND BIOSCIENCES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZALE, STEPHEN E.;TROIANO, GREG;ALI, MIR MUKKARAM;AND OTHERS;SIGNING DATES FROM 20091120 TO 20091123;REEL/FRAME:023593/0493

AS Assignment

Owner name: BIND THERAPEUTICS, INC., MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:BIND BIOSCIENCES, INC.;REEL/FRAME:030573/0152

Effective date: 20130401

AS Assignment

Owner name: PFIZER INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIND THERAPEUTICS, INC.;REEL/FRAME:041261/0721

Effective date: 20160801

FPAY Fee payment

Year of fee payment: 4